SCHEMBL4086013

SCHEMBL4086013

CC(C)(C)Cc1nc(-c2ccc3[nH]nc(-c4ccc5cc(OCCc6cccnc6)ccc5c4)c3c2)n[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 2/20 0.40
ROCK2 O75116 1/20 0.39
GRK2 P25098 1/20 0.39
TTK P33981 4/20 0.38
FGFR1 P11362 1/20 0.38
WNT1 P04628 2/20 0.38
FGFR4 P22455 1/20 0.38
MAPK8 P45983 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
CLK2 P49760 4/20 0.36
DYRK1A Q13627 4/20 0.36
CLK3 P49761 3/20 0.36
CHEK1 O14757 1/20 0.36
HRH4 Q9H3N8 1/20 0.36
CLK1 P49759 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
NTRK1 P04629 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13812277 0.92 FGFR1 (0.46) CSNK1DROCK2GRK2TTKFGFR1
SCHEMBL4090270 0.86 CSNK1D (0.59) CSNK1DFGFR1WNT1MAPK8CLK2
SCHEMBL13812061 0.80 CSNK1D (0.40) CSNK1DTTKWNT1MAPK8
SCHEMBL4084125 0.80 TBXAS1 (0.43) CSNK1DCYP19A1
SCHEMBL4084459 0.79 FGFR4 (0.45) CSNK1DTTKFGFR1FGFR4MAPK8
SCHEMBL13812272 0.79 TTK (0.39) CSNK1DTTKWNT1MAPK8
SCHEMBL13812073 0.78 CSNK1D (0.42) CSNK1DTTKMAPK8CLK2DYRK1A
SCHEMBL4170396 0.78 CYP19A1 (0.42) TTKFGFR1WNT1FGFR4MAPK8
SCHEMBL13812166 0.77 CSNK1D (0.43) CSNK1DTTKMAPK8CLK2DYRK1A
SCHEMBL4079733 0.77 CSNK1D (0.43) CSNK1DTTKMAPK8CLK2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 CSNK1D 702/4885ROCK2 441/4885GRK2 396/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 CSNK1D 687/4885ROCK2 447/4885GRK2 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.